FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283275436> ?p ?o ?g. }

• W4283275436 endingPage "3668" @default.
• W4283275436 startingPage "3658" @default.
• W4283275436 abstract "New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma.In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant received treatment with the following schedule: lenalidomide 10 mg Days (D)1-14, rituximab 375 mg/m2 D1, cisplatin 60 mg/m2 D1, gemcitabine 750 mg/m2 D1 and D8, and dexamethasone 20 mg D1-3, up to 6 cycles (induction phase), followed by lenalidomide 10 mg (or last lenalidomide dose received) D1-21 every 28 days (maintenance phase). Primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and monitorization of key circulating immune biomarkers (EU Clinical Trials Register number: EudraCT 2014-001620-29).After a median follow-up of 37 months, ORR was 60.2% [37.1% complete responses (CR) and 23.1% partial responses (PR)]. Median OS was 12 months (47 vs. 6 months in CR vs. no CR); median PFS was 9 months (34 vs. 5 months in CR vs. no CR). In the primary refractory population, ORR was 45.5% (21.2% CR and 24.3% PR). Most common grade 3-4 adverse events were thrombocytopenia (60.2%), neutropenia (60.2%), anemia (26.9%), infections (15.3%), and febrile neutropenia (14.1%). Complete responses were associated with a sharp decrease in circulating myeloid-derived suppressor cells and regulatory T cells.R2-GDP schedule is feasible and highly active in R/R DLBCL, including the primary refractory population. Immune biomarkers showed differences in responders versus progressors." @default.
• W4283275436 created "2022-06-23" @default.
• W4283275436 creator A5000964577 @default.
• W4283275436 creator A5004185974 @default.
• W4283275436 creator A5006715111 @default.
• W4283275436 creator A5008908552 @default.
• W4283275436 creator A5010454411 @default.
• W4283275436 creator A5014613098 @default.
• W4283275436 creator A5017039164 @default.
• W4283275436 creator A5025193090 @default.
• W4283275436 creator A5031374790 @default.
• W4283275436 creator A5032140246 @default.
• W4283275436 creator A5036402438 @default.
• W4283275436 creator A5038461805 @default.
• W4283275436 creator A5038909478 @default.
• W4283275436 creator A5041202787 @default.
• W4283275436 creator A5044904290 @default.
• W4283275436 creator A5051829676 @default.
• W4283275436 creator A5059430668 @default.
• W4283275436 creator A5068854589 @default.
• W4283275436 creator A5069930525 @default.
• W4283275436 creator A5070411650 @default.
• W4283275436 creator A5072577565 @default.
• W4283275436 creator A5072956698 @default.
• W4283275436 creator A5074661276 @default.
• W4283275436 creator A5076372006 @default.
• W4283275436 creator A5077037752 @default.
• W4283275436 creator A5078778722 @default.
• W4283275436 creator A5083176866 @default.
• W4283275436 creator A5084991678 @default.
• W4283275436 creator A5085015409 @default.
• W4283275436 creator A5086793519 @default.
• W4283275436 date "2022-06-21" @default.
• W4283275436 modified "2023-10-18" @default.
• W4283275436 title "Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis" @default.
• W4283275436 cites W1973532909 @default.
• W4283275436 cites W1976564639 @default.
• W4283275436 cites W1990765152 @default.
• W4283275436 cites W1994719395 @default.
• W4283275436 cites W2000302977 @default.
• W4283275436 cites W2006713638 @default.
• W4283275436 cites W2007627691 @default.
• W4283275436 cites W2025658051 @default.
• W4283275436 cites W2072646319 @default.
• W4283275436 cites W2100645234 @default.
• W4283275436 cites W2126772526 @default.
• W4283275436 cites W2133201432 @default.
• W4283275436 cites W2137017500 @default.
• W4283275436 cites W2149557304 @default.
• W4283275436 cites W2150587745 @default.
• W4283275436 cites W2158267770 @default.
• W4283275436 cites W2169014774 @default.
• W4283275436 cites W2171194005 @default.
• W4283275436 cites W2568946517 @default.
• W4283275436 cites W2598700764 @default.
• W4283275436 cites W2744261860 @default.
• W4283275436 cites W2767441088 @default.
• W4283275436 cites W2773804840 @default.
• W4283275436 cites W2797584152 @default.
• W4283275436 cites W2801763724 @default.
• W4283275436 cites W2903062212 @default.
• W4283275436 cites W2982852619 @default.
• W4283275436 cites W2984927918 @default.
• W4283275436 cites W3012464003 @default.
• W4283275436 cites W3016044607 @default.
• W4283275436 cites W3034162969 @default.
• W4283275436 cites W3122661941 @default.
• W4283275436 cites W3128028170 @default.
• W4283275436 cites W3132205831 @default.
• W4283275436 cites W3137124431 @default.
• W4283275436 cites W3161133732 @default.
• W4283275436 cites W3177202607 @default.
• W4283275436 cites W4385986623 @default.
• W4283275436 doi "https://doi.org/10.1158/1078-0432.ccr-22-0588" @default.
• W4283275436 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35727601" @default.
• W4283275436 hasPublicationYear "2022" @default.
• W4283275436 type Work @default.
• W4283275436 citedByCount "5" @default.
• W4283275436 countsByYear W42832754362020 @default.
• W4283275436 countsByYear W42832754362023 @default.
• W4283275436 crossrefType "journal-article" @default.
• W4283275436 hasAuthorship W4283275436A5000964577 @default.
• W4283275436 hasAuthorship W4283275436A5004185974 @default.
• W4283275436 hasAuthorship W4283275436A5006715111 @default.
• W4283275436 hasAuthorship W4283275436A5008908552 @default.
• W4283275436 hasAuthorship W4283275436A5010454411 @default.
• W4283275436 hasAuthorship W4283275436A5014613098 @default.
• W4283275436 hasAuthorship W4283275436A5017039164 @default.
• W4283275436 hasAuthorship W4283275436A5025193090 @default.
• W4283275436 hasAuthorship W4283275436A5031374790 @default.
• W4283275436 hasAuthorship W4283275436A5032140246 @default.
• W4283275436 hasAuthorship W4283275436A5036402438 @default.
• W4283275436 hasAuthorship W4283275436A5038461805 @default.
• W4283275436 hasAuthorship W4283275436A5038909478 @default.
• W4283275436 hasAuthorship W4283275436A5041202787 @default.
• W4283275436 hasAuthorship W4283275436A5044904290 @default.
• W4283275436 hasAuthorship W4283275436A5051829676 @default.
• W4283275436 hasAuthorship W4283275436A5059430668 @default.

• next